Molecular regulation of HDL metabolism and function: Implications for novel therapies

Journal of Clinical Investigation

Volumn 116, Issue 12, 2006, Pages 3090-3100

  Rader, Daniel J ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HUMAN; LIPOPROTEIN METABOLISM; MACROPHAGE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ARTERIOSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; HUMANS; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL;

EID: 33845320131     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30163     Document Type: Review

References (124)

1. Miller, G.J., and Miller, N.E. 1975. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet. 1:16-19.
2. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). 2001. Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA. 285:2486-2497.
3. Lewis, G.F., and Rader, D.J. 2005. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res. 96:1221-1232.
4. Glomset, J.A. 1968. The plasma lecithins:cholesterol acyltransferase reaction. J. Lipid Res. 9:155-167.
5. Ross, R., and Glomset, J.A. 1973. Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science. 180:1332-1339.
6. Barter, P.J., et al. 2004. Antiinflammatory properties of HDL. Circ. Res. 95:764-772.
7. Mineo, C., Deguchi, H., Griffin, J.H., and Shaul, P.W. 2006. Endothelial and antithrombotic actions of HDL. Circ. Res. 98:1352-1364.
8. Williamson, R., Lee, D., Hagaman, J., and Maeda, N. 1992. Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc. Natl. Acad. Sci. U. S. A. 89:7134-7138.
9. Schaefer, E.J., Heaton, W.H., Wetzel, M.G., and Brewer, H.B., Jr. 1982. Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease. Arteriosclerosis. 2:16-26.
10. Moore, R.E., et al. 2005. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ. Res. 97:763-771.
11. Rubin, E., Krauss, R., Spangler, E., Verstuyft, J., and Clift, S. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature. 353:265-267.
12. Plump, A., Scott, C., and Breslow, J. 1994. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc. Natl. Acad. Sci. U. S. A. 91:9607-9611.
13. Tangirala, R.K., et al. 1999. Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation. 100:1816-1822.
14. Mooradian, A.D., Haas, M.J., and Wong, N.C. 2004. Transcriptional control of apolipoprotein A-I gene expression in diabetes. Diabetes. 53:513-520.
15. Berthou, L., et al. 1996. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97:2408-2416.
16. Delerive, P., Galardi, C.M., Bisi, J.E., Nicodeme, E., and Goodwin, B. 2004. Identification of liver receptor homolog-1 as a novel regulator of apolipoprotein AI gene transcription. Mol. Endocrinol. 18:2378-2387.
17. Weng, W., and Breslow, J.L. 1996. Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility. Proc. Natl. Acad. Sci. U. S. A. 93:14788-14794.
18. Schultz, J.R., Verstuyft, J.G., Gong, E.L., Nichols, A.V., and Rubin, E.M. 1993. Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature. 365:762-764.
19. Warden, C.H., Hedrick, C.C., Qiao, J.-H., Castellani, L.W., and Lusis, A.J. 1993. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science. 261:469-472.
20. Wang, X., and Paigen, B. 2005. Genetics of variation in HDL cholesterol in humans and mice. Circ. Res. 96:27-42.
21. Ikewaki, K., Zech, L.A., Kindt, M., Brewer, H.B., Jr., and Rader, D.J. 1995. Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler.Thromb. Vasc. Biol. 15:306-312.
22. Rust, S., et al. 1999. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22:352-355.
23. Bodzioch, M., et al. 1999. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22:347-351.
24. Brooks-Wilson, A., et al. 1999. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22:336-345.
25. McNeish, J., et al. 2000. High density lipoprotein deficiency and foam cell accumulation in mice with targeted disruption of ATP-binding cassette transporter-1. Proc. Natl. Acad. Sci. U. S. A. 97:4245-4250.
26. Schaefer, E.J., et al. 1978. Metabolism of high-density lipoprotein apolipoproteins in Tangier disease. N. Engl. J. Med. 299:905-910.
27. Timmins, J.M., et al. 2005. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest. 115:1333-1342. doi:10.1172/ JCI200523915.
28. Brunham, L.R., et al. 2006. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest. 116:1052-1062. doi:10.1172/JCI27352.
29. Dietschy, J.M., and Turley, S.D. 2002. Control of cholesterol turnover in the mouse. J. Biol. Chem. 277:3801-3804.
30. Haghpassand, M., Bourassa, P.A., Francone, O.L., and Aiello, R.J. 2001. Monocyte/macrophage expression of ABCA1 has minimal contribution to plasma HDL levels. J. Clin. Invest. 108:1315-1320. doi:10.1172/JCI200112810.
31. Huuskonen, J., Olkkonen, V.M., Jauhiainen, M., and Ehnholm, C. 2001. The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis. 155:269-281.
32. Jiang, X.C., et al. 1999. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. J. Clin. Invest. 103:907-914.
33. Jiang, X., et al. 1996. Increased preaβ-high density lipoprotein, apolipoprotein AI, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein AI transgenes. J. Clin. Invest. 98:2373-2380.
34. Kuivenhoven, J.A., et al. 1997. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J. Lipid Res. 38:191-205.
35. Ng, D.S. 2004. Insight into the role of LCAT from mouse models. Rev. Endocr. Metab. Disord. 5:311-318.
36. Rader, D.J., et al. 1994. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin: cholesterol acyltransferase deficiency and fish-eye disease. J. Clin. Invest. 93:321-330.
37. Francone, O.L., Gong, E.L., Ng, D.S., Fielding, C.J., and Rubin, E.M. 1995. Expression of human lecithin-cholesterol acyltransferase in transgenic mice. Effect of human apolipoprotein AI and human apolipoprotein all on plasma lipoprotein cholesterol metabolism. J. Clin. Invest. 96:1440-1448.
38. Schwartz, C.C., VandenBroek, J.M., and Cooper, P.S. 2004. Lipoprotein cholesteryl ester production, transfer, and output in vivo in humans. J. Lipid Res. 45:1594-1607.
39. Silver, D.L., Wang, N., Xiao, X., and Tall, A.R. 2001. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J. Biol. Chem. 276:25287-25293.
40. Kozarsky, K.F., et al. 1997. Overexpression of the HDL receptor SR-B1 alters plasma HDL and bile cholesterol levels. Nature. 387:414-417.
41. Rigotti, A., et al. 1997. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc. Natl. Acad. Sci. U. S. A. 94:12610-12615.
42. Brundert, M., et al. 2005. Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler. Thromb. Vasc. Biol. 25:143-148.
43. Zhang, Y., et al. 2005. Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo. J. Clin. Invest. 115:2870-2874. doi:10.1172/ JCI25327.
44. Kozarsky, K.F., Donahee, M.H., Glick, J.M., Krieger, M., and Rader, D.J. 2000. Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler. Thromb. Vasc. Biol. 20:721-727.
45. Arai, T., Wang, N., Bezouevski, M., Welch, C., and Tall, A.R. 1999. Decreased atherosclerosis in heterozygous low density lipoprotein receptordeficient mice expressing the scavenger receptor BI transgene. J. Biol. Chem. 274:2366-2371.
46. Ueda, Y., et al. 2000. Relationship between expression levels and atherogenesis in scavenger receptor class B, type I transgenics. J. Biol. Chem. 275:20368-20373.
47. Trigatti, B., et al. 1999. Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology. Proc. Natl. Acad. Sci. U. S. A. 96:9322-9327.
48. Braun, A., et al. 2002. Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ. Res. 90:270-276.
49. Covey, S.D., Krieger, M., Wang, W., Penman, M., and Trigatti, B.L. 2003. Scavenger receptor class B type I-mediated protection against atherosclerosis in LDL receptor-negative mice involves its expression in bone marrow-derived cells. Arterioscler. Thromb. Vasc. Biol. 23:1589-1594.
50. Osgood, D., et al. 2003. Genetic variation at the scavenger receptor class B type I gene locus determines plasma lipoprotein concentrations and particle size and interacts with type 2 diabetes: the framingham study. J. Clin. Endocrinol. Metab. 88:2869-2879.
51. Agellon, L.B., et al. 1991. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:10796-10801.
52. Brown, M.L., et al. 1989. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature. 342:448-451.
53. Inazu, A., et al. 1990. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323:1234-1238.
54. Ikewaki, K., et al. 1993. Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J. Clin. Invest. 92:1650-1658.
55. De Grooth, G.J., et al. 2004. A review of CETP and its relation to atherosclerosis. J. Lipid Res. 45:1967-1974.
56. Rader, D.J. 2004. Inhibition of cholesteryl ester transfer protein activity: a new therapeutic approach to raising high-density lipoprotein. Curr. Atheroscler. Rep. 6:398-405.
57. De Grooth, G.J., et al. 2002. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation. 105:2159-2165.
58. Kuivenhoven, J.A., et al. 2005. Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am. J. Cardiol. 95:1085-1088.
59. Clark, R.W., et al. 2004. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler. Thromb. Vasc. Biol. 24:490-497.
60. Brousseau, M.E., et al. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350:1505-1515.
61. Davidson, M.H., McKenney, J.M., Shear, C.L., and Revkin, J.H. 2006. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 48:1774-1781.
62. Davidson, M.H., et al. 2003. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis. 169:113-120.
63. Curb, J.D., et al. 2004. A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly. J. Lipid Res. 45:948-953.
64. Boekholdt, S.M., and Thompson, J.F. 2003. Natural genetic variation as a tool in understanding the role of CETP in lipid levels and disease. J. Lipid Res. 44:1080-1093.
65. Boekholdt, S.M., et al. 2004. Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study. Circulation. 110:1418-1423.
66. Brousseau, M.E., et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25:1057-1064.
67. Ishigami, M., et al. 1994. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J. Biochem. (Tokyo). 116:257-262.
68. Matsuura, F., Wang, N., Chen, W., Jiang, X.C., and Tall, A.R. 2006. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway. J. Clin. Invest. 116:1435-1442. doi:10.1172/JCI27602.
69. Bays, H., McKenney, J., and Davidson, M. 2005. Torcetrapib/atorvastatin combination therapy. Expert Rev. Cardiovasc. Ther. 3:789-820.
70. Glass, C., Pittman, R.C., Weinstein, D.B., and Steinberg, D. 1983. Dissociation of tissue uptake of cholesterol ester from that of apoprotein A-I of rat plasma high density lipoprotein: selective delivery of cholesterol ester to liver, adrenal, and gonad. Proc. Natl. Acad. Sci. U. S. A. 80:5435-5439.
71. Moestrup, S.K., and Nielsen, L.B. 2005. The role of the kidney in lipid metabolism. Curr. Opin. Lipidol. 16:301-306.
72. Hammad, S.M., et al. 1999. Cubilin, the endocytic receptor for intrinsic factor-vitamin B12 complex, mediates high-density lipoprotein holoparticle endocytosis. Proc. Natl. Acad. Sci. U. S. A. 96:10158-10163.
73. Kozyraki, R., et al. 1999. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat. Med. 5:656-661.
74. Hammad, S.M., Barth, J.L., Knaak, C., and Argraves, W.S. 2000. Megalin acts in concert with cubilin to mediate endocytosis of high density lipoproteins. J. Biol. Chem. 275:12003-12008.
75. Christensen, E.I., and Gburek, J. 2004. Protein reabsorption in renal proximal tubule-function and dysfunction in kidney pathophysiology. Pediatr. Nephrol. 19:714-721.
76. Hayek, T., et al. 1992. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J. Clin. Invest. 90:505-510.
77. Webb, N.R., et al. 2002. Overexpression of SR-BI by adenoviral vector promotes clearance of apoA-I, but not apoB, in human apoB transgenic mice. J. Lipid Res. 43:1421-1428.
78. Lamarche, B., et al. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J. Clin. Invest. 103:1191-1199.
79. Jaye, M., et al. 1999. A novel endothelial-derived lipase that modulates HDL metabolism. Nat. Genet. 21:424-428.
80. Hirata, K., et al. 1999. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J. Biol. Chem. 274:14170-14175.
81. Ishida, T., et al. 2003. Endothelial lipase is a major determinant of HDL level. J. Clin. Invest. 111:347-355. doi:10.1172/JCI200316306.
82. Maugeais, C., et al. 2003. Dose-dependent acceleration of high-density lipoprotein catabolism by endothelial lipase. Circulation. 108:2121-2126.
83. Jin, W., Millar, J.S., Broedl, U., Glick, J.M., and Rader, D.J. 2003. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J. Clin. Invest. 111:357-362. doi:10.1172/JCI200316146.
84. Ma, K., et al. 2003. Endothelial lipase is a major genetic determinant for high-density lipoprotein concentration, structure, and metabolism. Proc. Natl. Acad. Sci. U. S. A. 100:2748-2753.
85. deLemos, A.S., Wolfe, M.L., Long, C.J., Sivapackianathan, R., and Rader, D.J. 2002. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation. 106:1321-1326.
86. Badellino, K.O., Wolfe, M.L., Reilly, M.P., and Rader, D.J. 2006. Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med. 3:e22.
87. Ishida, T., et al. 2004. Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J. Biol. Chem. 279:45085-45092.
88. Ko, K.W., Paul, A., Ma, K., Li, L., and Chan, L. 2005. Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice. J. Lipid Res. 46:2586-2594.
89. Mahley, R.W., Huang, Y., and Weisgraber, K.H. 2006. Putting cholesterol in its place: apoE and reverse cholesterol transport. J. Clin. Invest. 116:1226-1229. doi:10.1172/JCI28632.
90. Fidge, N.H. 1999. High density lipoprotein receptors, binding proteins, and ligands. J. Lipid Res. 40:187-201.
91. Martinez, L.O., et al. 2003. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature. 421:75-79.
92. Jacquet, S., et al. 2005. The nucleotide receptor P2Y13 is a key regulator of hepatic high-density lipoprotein (HDL) endocytosis. Cell. Mol. Life Sci. 62:2508-2515.
93. Carlson, L.A. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J. Intern. Med. 258:94-114.
94. Meyers, C.D., Kamanna, V.S., and Kashyap, M.L. 2004. Niacin therapy in atherosclerosis. Curr. Opin. Lipidol. 15:659-665.
95. Tunaru, S., et al. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat. Med. 9:352-355.
96. Cuchel, M., and Rader, D.J. 2006. Macrophage reverse cholesterol transport: key to the regression of atherosclerosis? Circulation. 113:2548-2555.
97. Van Eck, M., et al. 2006. Macrophage ATP-binding cassette transporter A1 overexpression inhibits atherosclerotic lesion progression in low-density lipoprotein receptor knockout mice. Arterioscler. Thromb. Vasc. Biol. 26:929-934.
98. Repa, J.J., and Mangelsdorf, D.J. 2002. The liver X receptor gene team: potential new players in atherosclerosis. Nat. Med. 8:1243-1248.
99. Wang, N., Lan, D., Chen, W., Matsuura, F., and Tall, A.R. 2004. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to highdensity lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 101:9774-9779.
100. Kennedy, M.A., et al. 2005. ABCG1 has a critical role in mediating cholesterol efflux to HDL and preventing cellular lipid accumulation. Cell Metab. 1:121-131.
101. Wang, N., Ranalletta, M., Matsuura, F., Peng, F., and Tall, A.R. 2006. LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL. Arterioscler. Thromb. Vasc. Biol. 26:1310-1316.
102. Ranalletta, M., et al. 2006. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 26:2308-2315.
103. Baldan, A., et al. 2006. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/-mice transplanted with Abcg1-/- bone marrow. Arterioscler. Thromb. Vasc. Biol. 26:2301-2307.
104. Naik, S.U., et al. 2006. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 113:90-97.
105. Terasaka, N., et al. 2003. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536:6-11.
106. Joseph, S.B., et al. 2002. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. U. S. A. 99:7604-7609.
107. Levin, N., et al. 2005. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25:135-142.
108. Li, A.C., and Glass, C.K. 2004. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J. Lipid Res. 45:2161-2173.
109. Groot, P.H., et al. 2005. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 46:2182-2191.
110. Chawla, A., et al. 2001. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell. 7:161-171.
111. Chinetti, G., et al. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7:53-58.
112. Li, A.C., et al. 2004. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J. Clin. Invest. 114:1564-1576. doi:10.1172/JCI200418730.
113. Oliver, W.R., Jr., et al. 2001. A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98:5306-5311.
114. Rothblat, G.H., et al. 1999. Cell cholesterol efflux: integration of old and new observations provides new insights. J. Lipid Res. 40:781-796.
115. Zhang, W., et al. 2003. Inactivation of macrophage scavenger receptor class B type I promotes atherosclerotic lesion development in apolipoprotein Edeficient mice. Circulation. 108:2258-2263.
116. Nanje, M.N., et al. 1996. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler. Thromb. Vasc. Biol. 16:1203-1214.
117. Eriksson, M., Carlson, L.A., Miettinen, T.A., and Angelin, B. 1999. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans. Circulation. 100:594-598.
118. Nissen, S.E., et al. 2003. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 290:2292-2300.
119. Rader, D.J. 2003. High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA. 290:2322-2324.
120. Brewer, H.B., Jr. 2004. Focus on high density lipoproteins in reducing cardiovascular risk. Am. Heart J. 148(Suppl.):S14-S18.
121. Navab, M., Anantharamaiah, G.M., Reddy, S.T., and Fogelman, A.M. 2006. Apolipoprotein A-I mimetic peptides and their role in atherosclerosis prevention. Nat. Clin. Pract. Cardiovasc. Med. 3:540-547.
122. Garber, D.W., et al. 2001. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J. Lipid Res. 42:545-552.
123. Navab, M., et al. 2002. Oral administration of an Apo A-I mimetic peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation. 105:290-292.
124. Navab, M., et al. 2004. Oral D-4F causes formation of pre-beta high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation. 109:3215-3220.